Related Experiment Videos
On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
1Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. mariopaolo.colombo@istitutotumori.mi.it.
Summary
Many patients do not respond to immune checkpoint inhibitors. Combining these with costimulatory antibodies may improve outcomes, but the sequence of administration is critical for efficacy.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Immune checkpoint inhibitors (ICIs) are a cornerstone of cancer therapy, but a significant proportion of patients eventually develop resistance or do not respond.
- Combination therapies involving ICIs and costimulatory antibodies are being explored to overcome resistance and enhance anti-tumor immunity.
Discussion:
- The efficacy of combining ICIs with costimulatory antibodies may depend on the specific sequence of administration.
- Understanding the optimal timing and order of these agents is crucial for maximizing therapeutic benefit and potentially overcoming non-response.
Key Insights:
- Sequential administration of immune checkpoint inhibitors and costimulatory antibodies may be necessary for additive therapeutic effects.
- The non-response to ICIs highlights the need for combination strategies and careful treatment sequencing.
Outlook:
- Further research is needed to determine the optimal sequencing strategies for combination immunotherapies.
- Investigating the immunological mechanisms underlying sequential administration will be key to developing more effective cancer treatments.